BR100 Increased By (0.86%)
BR30 Increased By (0.94%)
KSE100 Increased By (0.81%)
KSE30 Increased By (0.88%)
AGHA 6.45 Increased By ▲ 0.07 (1.1%)
BECO 4.39 Increased By ▲ 0.04 (0.92%)
BML 62.50 Decreased By ▼ -0.05 (-0.08%)
BOP 31.51 Increased By ▲ 0.12 (0.38%)
CNERGY 11.80 Increased By ▲ 0.07 (0.6%)
CSIL 5.85 Decreased By ▼ -0.06 (-1.02%)
FCCL 61.80 Increased By ▲ 0.09 (0.15%)
FFL 15.04 Increased By ▲ 0.25 (1.69%)
FNEL 1.30 Increased By ▲ 0.06 (4.84%)
KEL 6.34 Increased By ▲ 0.02 (0.32%)
KOSM 5.80 Decreased By ▼ -0.10 (-1.69%)
LOTCHEM 24.89 Increased By ▲ 0.20 (0.81%)
MLCF 105.75 Increased By ▲ 1.82 (1.75%)
NBP 174.62 Increased By ▲ 1.30 (0.75%)
NCPL 52.11 Increased By ▲ 0.28 (0.54%)
NPL 54.61 Increased By ▲ 0.58 (1.07%)
OGDC 318.80 Increased By ▲ 2.93 (0.93%)
PACE 9.30 Increased By ▲ 0.04 (0.43%)
PAEL 35.80 Increased By ▲ 0.22 (0.62%)
PIBTL 14.22 Increased By ▲ 0.56 (4.1%)
PPL 229.00 Increased By ▲ 2.93 (1.3%)
PRL 81.70 Increased By ▲ 1.42 (1.77%)
PTC 47.00 Increased By ▲ 0.36 (0.77%)
SSGC 23.98 Increased By ▲ 0.16 (0.67%)
TBL 9.26 Increased By ▲ 0.02 (0.22%)
TELE 7.67 Increased By ▲ 0.12 (1.59%)
TPL 24.85 Increased By ▲ 0.31 (1.26%)
TPLP 12.91 Decreased By ▼ -0.08 (-0.62%)
TREET 26.00 Increased By ▲ 0.02 (0.08%)
TRG 53.74 Increased By ▲ 0.41 (0.77%)
By

France’s Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong demand for its anti-inflammatory drug Dupixent, as well as vaccines and newer treatments.

It had previously said it expects annual sales to grow by mid-to-high single-digit percentage at constant currency rates.

The drugmaker also confirmed that it expects earnings to grow at a low double-digit percentage this year.

Sanofi has significantly amped up its R&D expenditure in recent years, a move that led it to abandon its long-term margin targets in 2023. This shift underscores its focus to capitalize on the success of its blockbuster drug Dupixent as it builds its next wave of growth drivers.

Sales of its asthma drug Dupixent rose 21.1% to 3.83 billion euros ($4.38 billion), compared to 3.74 billion euros expected on average by analysts in a company-provided poll.

Quarterly business operating income, excluding one-off items, rose by 3.3% to 2.46 billion euros, below the average analyst estimate of 2.57 billion euros in a poll posted on the company’s website.

Comments

Comments are closed for this article.